DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
Claim(s) 1-14 is/are rejected under 35 U.S.C. 103 as being unpatentable over Akiyama et al (JP S63183506 A) in view of beervanablog.com (One of the World's Most Unusual Beers: Sake).
In regard to claim 1, Akiyama et al discloses a killer toxin-containing powder having good storage stability (page 1 of machine translation).
Akiyama et al discloses that a killer toxin-containing powder has many application including stopping the fermentation of fermented liquid by killing yeast that is responsible for fermentation:
The killer toxin-containing powder of the present invention is effective in the brewing industry for killing wild or contaminating microorganisms in fruit juice or mash before and during fermentation, for stopping fermentation by adding it at the end of fermentation to kill the yeast used as the starter yeast, and for preventing microbial contamination in storage and maturation processes after fermentation is completed, as well as in products filled into containers (page 1 of machine translation).
Furthermore, when added to moromi, fruit juice, or sake brewing, it exhibits a bactericidal effect or an anti-microbial contamination effect, and when added at the end of fermentation of moromi, it exhibits a fermentation stopping effect (page 3 of machine translation).
Hence, Akiyama et al discloses adding killer toxin to a fermentation liquid produced by fermentation of moromi with yeast.
In regard to claims 1, Akiyama et al discloses conducting screening assay:
The powders containing each type of killer toxin obtained by the three methods were placed in 5 ml glass vials (transparent glass) and stored at 3°C, 22°C, and 30°C, and the changes in killer activity over time were monitored by the following method. The results are shown in Table 1 (pages 3 of machine translation)..
Instead of the Saccharomyces cerevisiae epaneae strain used in the "Killer Activity Assay" shown in Example 1, the strains shown in Table 7 were used as test bacteria, and the effect of the above-mentioned spray-dried powder solution against these strains was examined in a manner similar to that of the "Killer Activity Assay". As shown in Table 7, the solution of the above powder exhibited a bactericidal action against Saccharomyces cerevisiae, Candida glabrata, Kluyveromyces lactis, Pichiaembranefascens, Rhodotorula rubra, and Hansenula anomala (pages 5-6 of machine translation).
Akiyama et al discloses comparison of the experiment where zero killer toxin has been added (page 5 of the machine translation). This reads on conducting a first assay on beer, i.e.. before adding a killer toxin.
In regard to claims 1 and 2, Akiyama et al discloses:
Table 6 Example 6 16 (7) Koshu fruit juice [reducing sugar 21.2% (11/v)] Nissartan and chromomyces cerevisiae .. +5kyf-5x105105 cells were inoculated at 7 ml each and fermentation was carried out at 15°C. When the extract content reached 4.5% (W/V), the same spray-dried powder as used in Example 4 was added to a concentration of 10 μg/m+, and after gentle stirring, the mixture was allowed to stand for 2 hours and observed. As a result, the generation of carbon dioxide gas ceased and fermentation was stopped (page 5 bottom paragraph, [page 6 top paragraph pf the machine translation).
Hence, the fermentation was carried out until extract content reached 4.5 4.5% (W/V).
In regard to claim 1, the machine translation from Japanese discloses fermentation of fruit juice, moromi and sake. Akiyama et al does not disclose beer. Beervanablog.com discloses similarities between beer and sake production. Beervanablog.com discloses that sake is essentially rice beer. One of ordinary skill in the art would have been motivated to modify Akiyama et al in view of beervanablog.com and to employ the fermentation stopping technique in the production of any alcoholic beverage including beer in order to obtain a fermented product having desired degree of alcohol. Beer is produced similarly to sake by fermentation of wort with yeast to produce alcoholic beverage. Therefore, to employ the same process in the production of beer would have been obvious.
In regard to claim 3, Akiyama et al discloses adding more than one type of killer toxin:
Killer yeasts that produce the killer toxin used in the present invention include those belonging to the genera Saccharomyces, Candida, Hansenula, Kluyveromyces, Pichia, and Cryptococcus. In addition, the killer toxins used in the present invention include various types of killer toxins such as type 1 to type 1 killer toxins or a new type killer toxin produced by Candida vinea sW55 (FERM P-8350) (page 2 of machine translation).
In regard to claim 4, Akiyama et al discloses directly adding the killer toxin to the fermented liquid:
The killer toxin-containing powder of the present invention is effective in the brewing industry for killing wild or contaminating microorganisms in fruit juice or mash before and during fermentation, for stopping fermentation by adding it at the end of fermentation to kill the yeast used as the starter yeast, and for preventing microbial contamination in storage and maturation processes after fermentation is completed, as well as in products filled into containers (page 1 of machine translation).
Furthermore, when added to moromi, fruit juice, or sake brewing, it exhibits a bactericidal effect or an anti-microbial contamination effect, and when added at the end of fermentation of moromi, it exhibits a fermentation stopping effect (page 3 of machine translation).
In regard to claim 5, Akiyama et al discloses
Example I Saccharomyces cerevisiae NCYC232 (K+ type killer), Saccharomyces cerevisiae AST20413 (PBRM P-8407, K2 type killer), Saccharomyces cerevisiae NCYC761 (Ni3 type killer), Hansenula murakii NCYC500 (K type killer), and Candida vinea SW55 (FBRM P-8350, new type killer) were each cultured at 25°C for 2 days in YEPD-CP medium (medium containing 2% glucose, 2% peptone, and 1% yeast extract dissolved in 0.1 M citratephosphate buffer with a pH of 4.8) and inoculated into an Erlenmeyer flask containing 50 mL of YBPD-CP medium (pH 4.8) to a bacterial concentration of 105 cells/m3, and cultured stationarily at 20°C for 3 days. After cultivation, each culture solution was filtered through a 0.45 μm cellulose acetate membrane filter, and 20% (1'i/v) cyclodextrin powder candy (manufactured by Toyo Brewing Co., Ltd.) and 5% (w/v) glucose were added to the resulting culture solution, which was then divided into three fractions of 159 ml each (fractions 11 to 11), and powdered (page 3 of machine translation).
In regard to claims 6-9, Akiyama et al discloses either killer yeast or killer toxin can be used in the process:
The powdering process is roughly divided into two steps: a step of adding one or more selected from polysaccharides, sugars, sugar alcohols, and ammonium sulfate to the culture medium of killer yeast or an aqueous solution of killer toxin and mixing it, and a step of concentrating and powdering the mixture (page 2 of machine translation).
In regard to claims 12-13, Akiyama et al discloses conducting screening assay:
The powders containing each type of killer toxin obtained by the three methods were placed in 5 ml glass vials (transparent glass) and stored at 3°C, 22°C, and 30°C, and the changes in killer activity over time were monitored by the following method. The results are shown in Table 1 (pages 3 of machine translation)..
Instead of the Saccharomyces cerevisiae epaneae strain used in the "Killer Activity Assay" shown in Example 1, the strains shown in Table 7 were used as test bacteria, and the effect of the above-mentioned spray-dried powder solution against these strains was examined in a manner similar to that of the "Killer Activity Assay". As shown in Table 7, the solution of the above powder exhibited a bactericidal action against Saccharomyces cerevisiae, Candida glabrata, Kluyveromyces lactis, Pichiaembranefascens, Rhodotorula rubra, and Hansenula anomala (pages 5-6 of machine translation).
In regard to claim 10, Akiyama et al discloses:
Instead of the Saccharomyces cerevisiae epaneae strain used in the "Killer Activity Assay" shown in Example 1, the strains shown in Table 7 were used as test bacteria, and the effect of the above-mentioned spray-dried powder solution against these strains was examined in a manner similar to that of the "Killer Activity Assay". As shown in Table 7, the solution of the above powder exhibited a bactericidal action against Saccharomyces cerevisiae, Candida glabrata, Kluyveromyces lactis, Pichiaembranefascens, Rhodotorula rubra, and Hansenula anomala (pages 5-6 of machine translation).
In regard to claim 11, Akiyama et al discloses adding killer toxin in the amount sufficient/effective to deactivate the fungus (pages 5-6 of machine translation).
In regard to claim 18, Akiyama et al discloses
Example I Saccharomyces cerevisiae NCYC232 (K+ type killer), Saccharomyces cerevisiae AST20413 (PBRM P-8407, K2 type killer), Saccharomyces cerevisiae NCYC761 (Ni3 type killer), Hansenula murakii NCYC500 (K type killer), and Candida vinea SW55 (FBRM P-8350, new type killer) (page 3 of machine translation).
In regard to claims 11-13, one of ordinary skill in the art would have been motivated to conduct screening essay at different stages of the process and to use various measurements in order to ensure killing activity of killer toxin.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-14 rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-12 of U.S. Patent No. 12275923 B2. Although the claims at issue are not identical, they are not patentably distinct from each other because both sets of claims are directed to the method/process of controlling attenuation in a fermentation process comprising: culturing a fungus in a medium to produce beer, wherein the fungus is at least one of Saccharomyces, Dekkera, Brettanomyce, Candida, or Aspergillus; adding a killer toxin to the beer, wherein the killer toxin is added in an amount effective to deactivate the fungus; conducting a first screening assay on the beer before adding the killer toxin; and conducting a second screening assay on the beer after adding the killer toxin.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to VERA STULII whose telephone number is (571)272-3221. The examiner can normally be reached Monday-Friday 5:30AM-3:30PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Nikki Dees can be reached at 571-270-3435. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/VERA STULII/Primary Examiner, Art Unit 1791